AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11394491 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS applied over the median nerve for 15 minutes
Number of subjects: 30
Study 11394491 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS applied to the Hegyu acupuncture point (L.I.4) for 15 minutes
Number of subjects: 30
Study 11394491 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TENS)
Number of subjects: 30
Study 9591928 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrinone (1-270 microg x min(-1))
Number of subjects: 18
Study 9591928 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (1-270 microg x min(-1))
Number of subjects: 18
Study 9591928 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (5-1500 microg x min(-1))
Number of subjects: 18
Study 9591928 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (2-877 microg x min(-1))
Number of subjects: 18
Study 8209275 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-containing chemotherapy plus radiotherapy
Number of subjects: 500
Study 8209275 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 500
Study 8209275 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin/ifosfamide/cisplatin (MIC) plus radiotherapy
Number of subjects: 500
Study 3059277 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (10 mg/kg I.V. q 6 H, day -5 to +1)
Number of subjects: 60
Study 3059277 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vancomycin)
Number of subjects: 60
Study 30261905 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics (Bifidobacterium breve strain Yakult, Lactobacillus casei strain Shirota, and galactooligosaccharides)
Number of subjects: 72
Study 30261905 — intervention group
Group type: COMPARATOR
Intervention: No‐Synbiotics
Number of subjects: 72
Study 30261905 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics
Number of subjects: 72
Study 28257160 — intervention group
Group type: COMPARATOR
Intervention: Protein 0 g (control)
Number of subjects: 27
Study 28257160 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein 12.5 g
Number of subjects: 27
Study 28257160 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein 25 g
Number of subjects: 27
Study 28257160 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein 50 g
Number of subjects: 27
Study 28257160 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein 75 g
Number of subjects: 27
Study 26403339 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy at various doses (grouped as >0% to 12.5%, >12.5% to 25%, >25% to 50%, and >50% of target dose)
Number of subjects: 6682
Study 26403339 — intervention group
Group type: EXPERIMENTAL
Intervention: >0% to 12.5% of target dose
Number of subjects: 6682
Study 26403339 — intervention group
Group type: EXPERIMENTAL
Intervention: >12.5% to 25% of target dose
Number of subjects: 6682
Study 26403339 — intervention group
Group type: EXPERIMENTAL
Intervention: >25% to 50% of target dose
Number of subjects: 6682
Study 26403339 — intervention group
Group type: COMPARATOR
Intervention: No beta-blocker therapy
Number of subjects: 6682
Study 23454885 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to smoking cues in movies (one-hour movie clip with smoking characters)
Number of subjects: 65
Study 23454885 — intervention group
Group type: COMPARATOR
Intervention: Exposure to movies without smoking characters (control group)
Number of subjects: 65
Study 21290983 — intervention group
Group type: EXPERIMENTAL
Intervention: CinA+ (sugared chewing gum containing cinnamic aldehyde and natural flavors)
Number of subjects: 15
Study 21290983 — intervention group
Group type: EXPERIMENTAL
Intervention: CinA- (sugared chewing gum without cinnamic aldehyde but with natural flavors)
Number of subjects: 15
Study 21290983 — intervention group
Group type: COMPARATOR
Intervention: GB (non-sugared chewing gum base without any flavors and without cinnamic aldehyde)
Number of subjects: 15
Study 19085498 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL ropivacaine (0.2%) intraarticularly plus 30 mL saline in the extraarticular wound space
Number of subjects: 32
Study 19085498 — intervention group
Group type: COMPARATOR
Intervention: 20 mL ropivacaine (0.2%) intraarticularly plus 30 mL ropivacaine (0.2%) in the extraarticular wound space
Number of subjects: 32
Study 17205877 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 1% tropicamide and 10% phenylephrine (Group A)
Number of subjects: 80
Study 17205877 — intervention group
Group type: COMPARATOR
Intervention: Three doses of 1% tropicamide and 10% phenylephrine (Group B)
Number of subjects: 80
Study 17205877 — intervention group
Group type: COMPARATOR
Intervention: Comparison of pupil size between Group A and Group B
Number of subjects: 80
Study 14581307 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease Management Program (DMP) with 6 home visits by a cardiac-trained nurse
Number of subjects: 146
Study 14581307 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease Management Program (DMP)
Number of subjects: 146
Study 16049609 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg
Number of subjects: 40
Study 16049609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10609067 — intervention group
Group type: EXPERIMENTAL
Intervention: APF+ patients (positive for APF)
Number of subjects: 249
Study 10609067 — intervention group
Group type: EXPERIMENTAL
Intervention: RF+APF+ patients
Number of subjects: 249
Study 10609067 — intervention group
Group type: EXPERIMENTAL
Intervention: RF+APF- and RF-APF+ patients
Number of subjects: 249
Study 10609067 — intervention group
Group type: COMPARATOR
Intervention: RF+APF- patients
Number of subjects: 249
Study 10609067 — intervention group
Group type: COMPARATOR
Intervention: RF-APF+ patients
Number of subjects: 249
Study 10609067 — intervention group
Group type: COMPARATOR
Intervention: RF-APF- patients
Number of subjects: 249
Study 10609067 — intervention group
Group type: EXPERIMENTAL
Intervention: APF+ patients
Number of subjects: 249
Study 10609067 — intervention group
Group type: EXPERIMENTAL
Intervention: RF+ and RF- patients
Number of subjects: 249
Study 7577294 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural anaesthesia with Bupivacaine 0.5% (20 ml) at L2-3
Number of subjects: 10
Study 7577294 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural anaesthesia
Number of subjects: 10
Study 1850789 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive videodisc program (n = 42)
Number of subjects: 83
Study 1850789 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture method (n = 41)
Number of subjects: 83
Study 7261940 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol in fixed combinations with triamteren and hydrochlorothiazide (Dociteren)
Number of subjects: 19
Study 7261940 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol with increased diuretic component
Number of subjects: 19
Study 7261940 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol treatment
Number of subjects: 19
Study 7261940 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory tests during treatment
Number of subjects: 19
Study 28558941 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 24
Study 28558941 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 24
Study 25424991 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir (2 g four times daily)
Number of subjects: 119
Study 25424991 — intervention group
Group type: COMPARATOR
Intervention: Valganciclovir (900 mg daily)
Number of subjects: 119
Study 23406721 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led self-management support intervention
Number of subjects: 58
Study 20959530 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg/day) with exercise training (1.5-2 h/day, 3 days/wk)
Number of subjects: 44
Study 20959530 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone (30 mg/day) alone
Number of subjects: 44
Study 19212305 — intervention group
Group type: EXPERIMENTAL
Intervention: Current treatment for hepatitis C
Number of subjects: 170000000
Study 19212305 — intervention group
Group type: EXPERIMENTAL
Intervention: Specifically Targeted Antiviral Therapy for HCV (STAT-C)
Number of subjects: 170000000
Study 17556788 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10mg
Number of subjects: 2268
Study 17556788 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10mg
Number of subjects: 2268
Study 17556788 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg
Number of subjects: 2268
Study 15213207 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) 0.625 mg daily
Number of subjects: 2808
Study 15213207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2808
Study 15213207 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled hormone therapy (CEE combined with CEE plus MPA)
Number of subjects: 2808
Study 11711348 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 9
Study 11711348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 9549834 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (5 mg sublingual tablet)
Number of subjects: 11
Study 9549834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 7528449 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF) after successful cytoreductive chemotherapy
Number of subjects: 67
Study 7528449 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during induction, consolidation, and the first two cycles of maintenance chemotherapy
Number of subjects: 67
Study 3382060 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metaproterenol sulfate (MS) 0.4 mg/kg
Number of subjects: 10
Study 3382060 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metaproterenol sulfate (MS) 0.6 mg/kg
Number of subjects: 10
Study 3382060 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metaproterenol sulfate (MS) 0.8 mg/kg
Number of subjects: 10
Study 3382060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31416827 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (0.6 mg/kg)
Number of subjects: 1252
Study 31416827 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dexamethasone (0.15 mg/kg)
Number of subjects: 1252
Study 31416827 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (1 mg/kg)
Number of subjects: 1252
Study 27886678 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard patellar bone resection
Number of subjects: 0
Study 27886678 — intervention group
Group type: COMPARATOR
Intervention: Modified patellar bone resection
Number of subjects: 0
Study 25646337 — intervention group
Group type: COMPARATOR
Intervention: Iron‐folic acid (IFA) capsule
Number of subjects: 1391
Study 25646337 — intervention group
Group type: COMPARATOR
Intervention: Multiple micronutrients (MMN) capsule
Number of subjects: 1391
Study 25646337 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-g sachet of small‐quantity lipid‐based nutrient supplement (SQ‐LNS)
Number of subjects: 1391
Study 24029861 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band ultraviolet B (NB-UVB) exposures
Number of subjects: 14
Study 24029861 — intervention group
Group type: COMPARATOR
Intervention: Oral cholecalciferol 20 µg daily
Number of subjects: 14
Study 22204658 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month scale and polish
Number of subjects: 307
Study 22204658 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month scale and polish
Number of subjects: 307
Study 22204658 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-month scale and polish
Number of subjects: 307
Study 20818838 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin ER QD (total daily dose 1800 mg)
Number of subjects: 407
Study 20818838 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin ER DD (total daily dose 1800 mg)
Number of subjects: 407
Study 20818838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 407
Study 17995820 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate mix with 2.45 g of milk proteins
Number of subjects: 24
Study 17995820 — intervention group
Group type: COMPARATOR
Intervention: Chocolate mix without milk proteins
Number of subjects: 24
Study 15975326 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin‐converting enzyme inhibitors
Number of subjects: 0
Study 15975326 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarabose
Number of subjects: 0
Study 15975326 — intervention group
Group type: COMPARATOR
Intervention: Triflusal
Number of subjects: 0
Study 15975326 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 0
Study 15975326 — intervention group
Group type: COMPARATOR
Intervention: Vitamin treatment to lower homocysteine
Number of subjects: 0
Study 15975326 — intervention group
Group type: COMPARATOR
Intervention: Hormonal replacement in post‐menopausal women
Number of subjects: 0
Study 15975326 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic, anticoagulant and surgical treatments
Number of subjects: 0
Study 12072678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 12072678 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.015 mg/kg midazolam
Number of subjects: 98
Study 12072678 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg midazolam
Number of subjects: 98
Study 12072678 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06 mg/kg midazolam
Number of subjects: 98
Study 9854344 — intervention group
Group type: COMPARATOR
Intervention: No reminder
Number of subjects: 500
Study 9854344 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder (any type)
Number of subjects: 500
Study 9854344 — intervention group
Group type: EXPERIMENTAL
Intervention: Postal reminder
Number of subjects: 500
Study 9854344 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual telephone reminder
Number of subjects: 500
Study 9854344 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated telephone reminder
Number of subjects: 500
Study 9854344 — intervention group
Group type: EXPERIMENTAL
Intervention: All reminder methods combined
Number of subjects: 500
Study 7830025 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity intervention
Number of subjects: 76
Study 7830025 — intervention group
Group type: COMPARATOR
Intervention: Medium-intensity intervention
Number of subjects: 76
Study 2361810 — intervention group
Group type: COMPARATOR
Intervention: Exercise only (E)
Number of subjects: 121
Study 2361810 — intervention group
Group type: COMPARATOR
Intervention: Energy restriction only (D)
Number of subjects: 121
Study 2361810 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 121
Study 467206 — intervention group
Group type: EXPERIMENTAL
Intervention: X-Prep Liquid
Number of subjects: 0
Study 467206 — intervention group
Group type: EXPERIMENTAL
Intervention: Divided dose of X-Prep Liquid
Number of subjects: 0
Study 467206 — intervention group
Group type: COMPARATOR
Intervention: Castor oil
Number of subjects: 0
Study 30701704 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-free microcrystalline hydroxyapatite (HAP) dentifrice
Number of subjects: 150
Study 30701704 — intervention group
Group type: COMPARATOR
Intervention: 1400 ppm fluoride control dentifrice
Number of subjects: 150
Study 28723943 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress condition
Number of subjects: 0
Study 28723943 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 25751215 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (81 mg)
Number of subjects: 1228
Study 25751215 — intervention group
Group type: COMPARATOR
Intervention: Placebo (folic acid)
Number of subjects: 1228
Study 23599353 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation (HBCR)
Number of subjects: 100
Study 23599353 — intervention group
Group type: COMPARATOR
Intervention: In-hospital rehabilitation
Number of subjects: 100
Study 21561348 — intervention group
Group type: EXPERIMENTAL
Intervention: Trocar-guided transvaginal polypropylene-mesh repair kit
Number of subjects: 389
Study 21561348 — intervention group
Group type: COMPARATOR
Intervention: Traditional colporrhaphy
Number of subjects: 389
Study 19453810 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-compound scalp formulation (calcipotriol 50 microg/g plus betamethasone 0.5 mg/g as dipropionate; Xamiol)
Number of subjects: 312
Study 19453810 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol scalp solution (50 microg/mL; Daivonex)
Number of subjects: 312
Study 16952680 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative reading
Number of subjects: 17
Study 16952680 — intervention group
Group type: COMPARATOR
Intervention: No preoperative reading
Number of subjects: 17
Study 14872413 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 microg/kg rFVIIa within 1 to 2 hours of bleed onset
Number of subjects: 0
Study 14872413 — intervention group
Group type: COMPARATOR
Intervention: 90 microg/kg rFVIIa every 2 to 3 hours for two or three doses
Number of subjects: 0
Study 11380520 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 16
Study 11380520 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 16
Study 9250456 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 75
Study 9250456 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 75
Study 8488916 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure patching (group 1)
Number of subjects: 27
Study 8488916 — intervention group
Group type: EXPERIMENTAL
Intervention: Light patching (group 2)
Number of subjects: 27
Study 8488916 — intervention group
Group type: COMPARATOR
Intervention: Unpatched fellow eye (group 3)
Number of subjects: 27
Study 3631470 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine 3 mg
Number of subjects: 60
Study 3631470 — intervention group
Group type: COMPARATOR
Intervention: Pethidine 15 mg
Number of subjects: 60
Study 31952047 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate (NaHCO3) supplementation (0.3 g/kg body mass)
Number of subjects: 32
Study 31952047 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplements (amylum solani, magnesium stearate, and sunflower oil capsules)
Number of subjects: 32
Study 31952047 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate (NaHCO3) supplementation
Number of subjects: 32
Study 29683200 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-axis, in-plane approach
Number of subjects: 40
Study 29683200 — intervention group
Group type: COMPARATOR
Intervention: Short-axis, out-of-plane approach
Number of subjects: 40
Study 25818161 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (100 mg/day)
Number of subjects: 64
Study 25818161 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA
Number of subjects: 64
Study 25818161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 24769385 — intervention group
Group type: EXPERIMENTAL
Intervention: GrandioSO (conventional viscosity)
Number of subjects: 47
Study 24769385 — intervention group
Group type: EXPERIMENTAL
Intervention: GrandioSO Heavy Flow (flowable viscosity)
Number of subjects: 47
Study 24769385 — intervention group
Group type: COMPARATOR
Intervention: Both materials (GrandioSO and GrandioSO Heavy Flow)
Number of subjects: 47
Study 22685233 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous glargine (0.25 U/kg body weight)
Number of subjects: 61
Study 22685233 — intervention group
Group type: COMPARATOR
Intervention: Control group (no glargine)
Number of subjects: 61
Study 20368053 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (CFNB) after combined spinal and epidural anesthesia (CSEA)
Number of subjects: 60
Study 20368053 — intervention group
Group type: COMPARATOR
Intervention: Continuous femoral nerve block (CFNB) before combined spinal and epidural anesthesia (CSEA)
Number of subjects: 60
Study 18657398 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation
Number of subjects: 151
Study 18657398 — intervention group
Group type: COMPARATOR
Intervention: Work therapy
Number of subjects: 151
Study 15378185 — intervention group
Group type: EXPERIMENTAL
Intervention: Palladium-103 or iodine-125 seed implantation
Number of subjects: 38
Study 11344179 — intervention group
Group type: COMPARATOR
Intervention: HRT-only (conjugated equine estrogens 0.625 mg)
Number of subjects: 524
Study 11344179 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined risedronate-HRT (risedronate 5 mg + conjugated equine estrogens 0.625 mg)
Number of subjects: 524
Study 11344179 — intervention group
Group type: COMPARATOR
Intervention: HRT-only
Number of subjects: 524
Study 11344179 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined risedronate-HRT
Number of subjects: 524
Study 9699433 — intervention group
Group type: EXPERIMENTAL
Intervention: Restored NCCL with resin-modified polyalkenoate (glass-ionomer) cement (Group 1)
Number of subjects: 40
Study 9699433 — intervention group
Group type: EXPERIMENTAL
Intervention: Restored NCCL with adhesive composite resin system (Group 2)
Number of subjects: 40
Study 9699433 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrestored NCCL (Group 3)
Number of subjects: 40
Study 9699433 — intervention group
Group type: COMPARATOR
Intervention: Control group with no NCCL (Group 4)
Number of subjects: 40
Study 7859805 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomycin (1.5 g per day)
Number of subjects: 27
Study 7859805 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin and neomycin in combination
Number of subjects: 27
Study 7859805 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitostanol ester (1.5 g per day)
Number of subjects: 27
Study 7859805 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin alone
Number of subjects: 27
Study 7859805 — intervention group
Group type: COMPARATOR
Intervention: Neomycin
Number of subjects: 27
Study 2681592 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 10
Study 2681592 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 10
Study 200256 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microgram of ethinyl oestradiol
Number of subjects: 50